Stocks › DBVT
DBV Technologies S.A.
DBVT·Nasdaq·USD
$9.02
-0.40 (-4.25%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
DBVT
DBV Technologies S.A. · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
DBVTS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of DBVT by members of U.S. Congress · 6 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Sale $15,001 - $50,000 |
Dec 21, 2017 | Dec 15, 2017 | Filing ↗ |
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Purchase $1,001 - $15,000 |
Mar 23, 2016 | Mar 8, 2016 | Filing ↗ |
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Purchase $1,001 - $15,000 |
Feb 8, 2016 | Jan 29, 2016 | Filing ↗ |
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Purchase $1,001 - $15,000 |
Jan 27, 2016 | Jan 11, 2016 | Filing ↗ |
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Sale $1,001 - $15,000 |
Dec 21, 2015 | Dec 9, 2015 | Filing ↗ |
James B. RenacciHouse · R · OH |
DBVTDBV Technologies S.A. · Stock |
Purchase $1,001 - $15,000 |
Nov 23, 2015 | Nov 10, 2015 | Filing ↗ |
Whale Activity
Position changes in DBVT reported for 2026-09-30 by 83 institutional filers
- Increased17
- New5
- Held15
- Decreased23
- Closed20
- No prior filing3
| Filer | Shares | Value | Change |
|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 3.7M | $43.0M | new |
| MPM BioImpact LLC | 3.0M | $35.8M | decreased |
| Siren, L.L.C. | 2.4M | $27.7M | increased |
| ADAR1 Capital Management, LLC | 2.0M | $23.6M | increased |
| Vivo Capital, LLC | 1.8M | $21.7M | held |
| Artisan Partners Limited Partnership | 1.6M | $18.6M | increased |
| BAKER BROS. ADVISORS LP | 1.5M | $17.2M | held |
| UBS Group AG | 1.4M | $16.9M | increased |
| PERCEPTIVE ADVISORS LLC | 1.1M | $13.4M | decreased |
| Patient Square Capital LP | 1.1M | $13.0M | increased |
| Octagon Capital Advisors LP | 574.2K | $6.8M | held |
| MILLENNIUM MANAGEMENT LLC | 553.0K | $6.5M | increased |
Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.
Insider Trading
Net shares bought (+) or sold (−) on the open market by DBVT insiders, by quarter · Form 4
Recent Insider Transactions
37 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Mohideen PharisChief Medical Officer | Sale | −464 | $2.70 | $1K | Jul 29, 2026 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −534 | n/c | — | Jan 29, 2026 | Form 4 ↗ |
| EPIC Bpifrance | Sale | −1.3M | n/c | — | Dec 18, 2025 | Form 4 ↗ |
| EPIC Bpifrance | Sale | −40.0K | n/c | — | Dec 17, 2025 | Form 4 ↗ |
| EPIC Bpifrance | Sale | −2.0M | n/c | — | Dec 17, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Grant / award | +44.0K | $0.00 | $0 | Nov 21, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −1,624 | n/c | — | Nov 21, 2025 | Form 4 ↗ |
| Trapp Kevin MichaelChief Commercial Officer | Grant / award | +55.0K | $0.00 | $0 | Nov 21, 2025 | Form 4 ↗ |
| Boucinha VirginieChief Financial Officer | Grant / award | +32.0K | $0.00 | $0 | Nov 21, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −6,496 | n/c | — | Nov 20, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −464 | n/c | — | Jul 29, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −397 | n/c | — | May 22, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −600 | n/c | — | Jan 30, 2025 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −565 | $0.57 | $322 | Nov 25, 2024 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −342 | $0.53 | $181 | Nov 22, 2024 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −2,350 | $0.54 | $1K | Nov 21, 2024 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Grant / award | +35.0K | $0.00 | $0 | Nov 21, 2024 | Form 4 ↗ |
| Boucinha VirginieChief Financial Officer | Grant / award | +19.0K | $0.00 | $0 | Nov 21, 2024 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −1,785 | $0.98 | $2K | Jul 29, 2024 | Form 4 ↗ |
| Mohideen PharisChief Medical Officer | Sale | −660 | n/c | — | May 24, 2024 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding DBVT · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Artisan International Small-Mid Fund Artisan Partners Funds Inc. | 840.3K | $13.8M | 0.54% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund Fidelity Advisor Series VII | 428.8K | $5.8M | 0.26% | Jul 31, 2026 |
| Tax-Managed U.S. Mid & Small Cap Fund RUSSELL INVESTMENT CO | 45.1K | $947K | 0.05% | Apr 30, 2026 |
| AdvisorShares Dorsey Wright ADR ETF AdvisorShares Trust | 43.7K | $716K | 1.72% | Jun 30, 2026 |
| U.S. Small Cap Equity Fund RUSSELL INVESTMENT CO | 22.7K | $307K | 0.03% | Jul 31, 2026 |
| U.S. Small Cap Equity Fund RUSSELL INVESTMENT FUNDS | 5,834 | $96K | 0.04% | Jun 30, 2026 |
| ActivePassive International Equity ETF Trust for Professional Managers | 4,402 | $61K | 0.01% | Aug 31, 2026 |
| Steward Values Enhanced International Fund Steward Funds Inc | 4,051 | $55K | 0.02% | Jul 31, 2026 |
| Lord Abbett Health Care Fund LORD ABBETT SECURITIES TRUST | 2,973 | $40K | 0.47% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund Fidelity Concord Street Trust | 1,509 | $21K | 0.00% | Aug 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list DBVT's shares (CUSIP 23306J309), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- MPM BioImpact LLCSCHEDULE 13G/A · passive (13G) · 15.2M shares4.8%
Nov 13, 2026 · ↗ - Raymond DebbaneSCHEDULE 13G/A · passive (13G) · 24.7M shares7.9%
Nov 12, 2026 · ↗ - Ulys, L.L.C.SCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
Nov 12, 2026 · ↗ - Avicenna Life Sci Master GP LLCSCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
Nov 12, 2026 · ↗ - Avicenna Life Sci Master Fund LPSCHEDULE 13G/A · passive (13G) · 1.6M shares0.5%
Nov 12, 2026 · ↗ - Siren, L.L.C.SCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
Nov 12, 2026 · ↗ - Invus Global Management, LLCSCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
Nov 12, 2026 · ↗ - Invus Public Equities Advisors, LLCSCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
Nov 12, 2026 · ↗ - Invus Public Equities, L.P.SCHEDULE 13G/A · passive (13G) · 23.1M shares7.3%
Nov 12, 2026 · ↗ - MPM BioImpact LLCSCHEDULE 13G/A · passive (13G) · 18.3M shares6.2%
Aug 14, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming dbv technologies as client
- WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q3 · HCR$30K
Filing ↗ - WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q2 · HCR$30K
Filing ↗ - WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2026 Q1 · HCR$30K
Filing ↗ - WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2025 Q4 · HCR$40K
Filing ↗ - WINNING STRATEGIES WASHINGTONDBV TECHNOLOGIES · 2025 Q3 · HCR$40K
Filing ↗
Government Contracts
Federal awards to DBV Technologies S.A. · USAspending
No federal contract awards found for DBV Technologies S.A..
U.S. Patents
Recent USPTO applications naming DBV Technologies S.A.
No USPTO patent applications found for DBV Technologies S.A..
Annual Financials
From DBVT's 10-K filings · XBRL
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $5.6M | $4.2M | $15.7M | $4.8M | $5.7M |
| Operating income | -$147.1M | -$116.6M | -$76.4M | -$96.6M | -$98.6M |
| Net income | -$146.9M | -$113.9M | -$72.7M | -$96.3M | -$97.8M |
| Diluted EPS | -$1.05 | -$1.17 | -$0.76 | -$1.24 | -$1.78 |
| Operating cash flow | -$121.2M | -$104.5M | -$79.7M | -$55.7M | -$108.2M |
| Cash and equivalents | $194.2M | $32.5M | $141.4M | $209.2M | $77.3M |
| Total assets | $233.7M | $65.7M | $183.0M | $246.5M | $146.7M |
| Total liabilities | $64.9M | $38.3M | $42.8M | $52.1M | $47.4M |
| Shareholders' equity | $168.8M | $27.4M | $140.2M | $194.5M | $99.3M |
As DBV Technologies S.A. tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Mar 26, 2026 ↗
Stock Splits
Every split and reverse split in the price history
- 1-for-5Reverse splitNov 29, 2024
- 1-for-2Reverse splitJun 7, 2024
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 2.02, 9.01Results of operationsOct 28, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsSep 30, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsJul 16, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 29, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeJun 5, 2026
EDGAR ↗ - 8-K · Items 5.03, 5.07, 9.01Bylaw amendment · Shareholder voteJun 3, 2026
EDGAR ↗ - 8-K · Items 5.02, 9.01Officer / director changeMay 5, 2026
EDGAR ↗
About DBV Technologies S.A.
From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersCHATILLON
IncorporatedI0
SEC CIK0001613780 ↗

